CSPC PHARMA (01093) Signs Strategic Collaboration and Licensing Agreement with AstraZeneca for Innovative Long-Acting Peptide Drug Development

Stock News01-30

CSPC PHARMA (01093) announced that the Group has entered into a strategic R&D collaboration and licensing agreement with global biopharmaceutical leader AstraZeneca PLC. The partnership will leverage the Group's proprietary sustained-release drug delivery technology platform and its AI-powered peptide drug discovery platform to develop innovative long-acting peptide drugs. The Group's long-acting technology enables the sustained release of peptide drugs, allowing for dosing intervals of once-monthly or longer. Products developed on this platform are ready-to-use, simple to administer, support patient self-administration, and can effectively improve treatment adherence for populations requiring long-term medication. Concurrently, the Group's AI peptide drug discovery platform can rapidly design and screen candidate molecules for drug targets, with systematic optimization across dimensions such as efficacy, selectivity, and signaling bias. Under the terms of the agreement, the Group will engage in a comprehensive strategic collaboration with AstraZeneca on the discovery of innovative peptide molecules and the development of long-acting delivery products. In addition to advancing the existing preclinical long-acting peptide pipeline, the Group will also discover and develop other innovative long-acting peptide products for AstraZeneca. AstraZeneca will obtain global exclusive rights (excluding Mainland China, Hong Kong, Macau, and Taiwan) to the Group's once-monthly injectable weight management product portfolio. This portfolio includes one clinical-ready project, SYH2082 (a long-acting GLP1R/GIPR agonist advancing to Phase I clinical trials), and three preclinical-stage R&D projects with different mechanisms of action, aimed at providing more durable therapeutic benefits for populations with obesity and weight-related issues. The two parties will also collaborate on four additional new projects utilizing these platforms. According to the agreement's terms and conditions, the Group will grant AstraZeneca an exclusive license to develop, manufacture, and commercialize the relevant licensed products globally (excluding Mainland China, Hong Kong, Macau, and Taiwan), while the Group will retain the rights to these products in Mainland China, Hong Kong, Macau, and Taiwan. For AstraZeneca's access to the eight projects and the use of these platforms, the Group will receive a $1.2 billion upfront payment. It is also eligible for up to $3.5 billion in potential R&D milestone payments and up to $13.8 billion in potential sales milestone payments, plus sales royalties of up to a double-digit percentage based on the annual net sales of the relevant licensed products.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment